Core Viewpoint - Zhongheng Group (600252.SH) has completed its share repurchase program, exceeding the lower limit of the total repurchase funds outlined in the plan [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased a total of 118 million shares, accounting for 3.5649% of the total share capital [1] - The highest repurchase price was 2.93 CNY per share, while the lowest was 2.30 CNY per share, with an average repurchase price of 2.55 CNY per share [1] - The total amount of funds used for the repurchase reached 300 million CNY, excluding transaction fees such as stamp duty and commission [1]

Core Viewpoint - Zhongheng Group has successfully completed its share repurchase plan for 2025, demonstrating confidence in its future development and intrinsic value [1][2] Group 1: Share Repurchase Details - The company repurchased a total of 118 million shares, accounting for 3.56% of its total share capital, at an average price of 2.55 yuan per share, with a total expenditure of 301 million yuan [1] - The repurchase plan was initiated in February 2025, and all repurchased shares will be canceled to reduce registered capital, changing the total share capital from 3.313 billion shares to 3.195 billion shares [1] Group 2: Market Impact and Confidence - Market analysts view the share repurchase as a positive signal that effectively boosts market confidence, reflecting the company's judgment on the reasonableness of its current stock price and its commitment to optimizing capital structure for high-quality development [1][2] - Since the implementation of the repurchase plan, Zhongheng Group has consistently advanced its repurchase efforts, notably increasing its repurchase volume in April amid market volatility, acquiring approximately 42.15 million shares for 101 million yuan [2] Group 3: Historical Context and Future Strategy - This marks Zhongheng Group's third share repurchase after those in 2018 and 2024, with a total of 730 million yuan spent on repurchasing over 291 million shares in recent years [2] - The company has also emphasized shareholder rights protection through consistent cash dividends, with total dividends exceeding 3.5 billion yuan since its listing [2] - Looking ahead, Zhongheng Group aims to focus on a dual-driven strategy of industry and capital to ensure that its investment value reflects its quality and supports high-quality development [2]

Core Viewpoint - The legal opinion letter indicates that Guangxi Investment Group Co., Ltd. and its concerted actions are exempt from making a tender offer due to the share repurchase by Guangxi Wuzhou Zhongheng Group Co., Ltd. which resulted in their combined shareholding exceeding 30% [2][14]. Group 1: Acquisition Details - Guangxi Investment Group is acquiring shares in Guangxi Wuzhou Zhongheng Group, which has led to a passive increase in their shareholding above 30% due to the company's share repurchase [2][10]. - The repurchase plan involves using between RMB 300 million and RMB 500 million to buy back shares at a price not exceeding RMB 3.80 per share, with the repurchase period set for six months [11][12]. Group 2: Company Qualifications - Guangxi Investment Group is a state-owned limited liability company with a registered capital of RMB 2.3 billion, established on March 8, 1996, and is currently in good standing [6][7]. - Guangxi Health Industry Group Co., Ltd., a wholly-owned subsidiary of Guangxi Investment Group, is also qualified as a concerted action party in this acquisition [8][10]. Group 3: Legal Compliance - Both Guangxi Investment Group and its concerted action party do not fall under any prohibitive conditions outlined in the Acquisition Management Measures, confirming their eligibility for the acquisition [10][11]. - The acquisition meets the criteria for exemption from making a tender offer as stipulated in the Share Repurchase Rules and the Acquisition Management Measures [14].

Summary of Key Points Core Viewpoint - The company has successfully completed a share buyback program, which involved repurchasing a total of 118,117,197 shares, representing 3.5649% of its total share capital, with the aim of reducing registered capital and enhancing shareholder value [1][2]. Group 1: Buyback Plan Details - The buyback plan was first disclosed on January 25, 2025, with an implementation period from February 26, 2025, to August 25, 2025 [1]. - The expected buyback amount was set between 300 million yuan and 500 million yuan, with a maximum buyback price of 3.80 yuan per share [1]. - The actual buyback price ranged from 2.30 yuan to 2.93 yuan per share, with an average buyback price of 2.55 yuan per share [2]. Group 2: Implementation and Results - The company initiated the buyback on April 10, 2025, and completed it by the end of the designated period, exceeding the lower limit of the planned buyback amount [2]. - The total funds used for the buyback amounted to approximately 301 million yuan, excluding transaction fees [2]. - The execution of the buyback plan was consistent with the originally disclosed plan, and it is expected to positively impact investor confidence and the company's market image [2]. Group 3: Share Cancellation and Capital Reduction - The company has followed legal procedures for notifying creditors regarding the cancellation of the repurchased shares [4]. - Following the cancellation, the total share capital will decrease from 3,313,345,567 shares to 3,195,228,370 shares [5]. - The controlling shareholder's stake will increase from 29.08% to 30.16% as a result of the share cancellation, but this will not lead to a change in control [5]. Group 4: Future Implications - The buyback is seen as a strategic move to bolster the company's long-term development and maintain the interests of all investors [2]. - The company will proceed with the necessary procedures for share cancellation and registration changes [7].

证券代码：600252 证券简称：中恒集团 公告编号：临2025-74 广西梧州中恒集团股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 重要内容提示： | | | | | | --- | --- | --- | --- | --- | | 回购方案首次披露日 | 2025/1/25 | | | | | 回购方案实施期限 | 年 月 月 2025 2 26 日~2025 25 | 年 | 8 | 日 | | 预计回购金额 | 30,000万元~50,000万元 | | | | | 回购价格上限 | 3.80元/股 | | | | | 回购用途 | √减少注册资本 | | | | | | □用于员工持股计划或股权激励 | | | | | | □为维护公司价值及股东权益 | | | | | 实际回购股数 | 11,811.7197万股 | | | | | 实际回购股数占总股本比例 | 3.5649% | | | | | 实际回购金额 | 30,102.1107万元 | | | ...

北京市建国门北大街 8 号华润大厦 20 层 邮编：100005 电话：(86-10) 8519-1300 传真：(86-10) 8519-1350 junhebj@junhe.com 北京市君合律师事务所 关于广西投资集团有限公司及其一致行动人 免于发出要约事宜 一、收购人及其一致行动人的主体资格 之法律意见书 致：广西投资集团有限公司 北京市君合律师事务所（以下简称"本所"）是在中国北京市司法局注册的律 师事务所，具备在中国从事法律服务的资格。本所接受广西投资集团有限公司（以 下简称"广投集团"或"收购人"）的委托，就广西梧州中恒集团股份有限公司（以 下简称"中恒集团"）注销回购股份导致广投集团及其一致行动人合计持股比例被 动超过 30%（以下简称"本次收购"）所涉及的免于发出要约的有关事宜，出具本 法律意见书。 为出具本法律意见书之目的，本所律师依据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司收购管理办法》（以下简称"《收购管理办法》"）及 《上市公司股份回购规则》（以下简称"《股份回购规则》"）等中国现行法律、行 政法规、部门规章及规范性文件之规定，审阅了广投集团提供的与本次收购相关 ...

来源：金融界 天眼查商业履历信息显示，广西梧州中恒集团股份有限公司，成立于1993年，位于梧州市，是一家以从 事医药制造业为主的企业。企业注册资本345148.9454万人民币，实缴资本5744万人民币。公司法定代 表人为杨金海。 通过天眼查大数据分析，广西梧州中恒集团股份有限公司共对外投资了32家企业，参与招投标项目104 次，知识产权方面有商标信息5条，此外企业还拥有行政许可13个。 金融界消息 截至2025年8月25日收盘，中恒集团（600252）报收于2.87元，下跌0.35%，换手率2.17%， 成交量71.56万手，成交金额2.06亿元。 资金流向方面，今日主力资金净流出2637.30万元，占比成交额12.8%。其中，超大单净流出2500.49万 元、占成交额12.14%，大单净流出136.81万元、占成交额0.66%，中单净流出流入1533.70万元、占成交 额7.45%，小单净流入1103.60万元、占成交额5.36%。 中恒集团最新一期业绩显示，截至2025一季报，公司营业总收入7.42亿元、同比减少7.92%，归属净利 润1826.71万元，同比减少66.61%，扣非净利润1577.21万 ...

Group 1 - The core point of the article is that Zhongheng Group's subsidiary, Laimei Pharmaceutical, has approved a guarantee for Chongqing Laimei Longyu Pharmaceutical Co., Ltd. to secure a credit facility of 10 million RMB from Hengfeng Bank [2][3] - The board and supervisory meetings of Laimei Pharmaceutical took place on August 20, 2025, where the guarantee proposal was reviewed and approved [2] - The loan term for the credit facility is set for one year [2]

Core Viewpoint - The company, Guangxi Wuzhou Zhongheng Group Co., Ltd., has announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., will provide a guarantee for its wholly-owned subsidiary, Chongqing Laimei Longyu Pharmaceutical Co., Ltd., to secure a credit facility of RMB 10 million from Hengfeng Bank [2][3]. Group 1: Guarantee Details - The guarantee involves a credit facility of RMB 10 million with a loan term of one year, and there is no counter-guarantee involved [2]. - The company has approved a total credit limit of up to RMB 5 billion for 2025, with a maximum guarantee amount of RMB 2.5 billion [3]. - The guarantee is within the approved credit limit and does not require further board or shareholder approval [3]. Group 2: Subsidiary Information - Laimei Longyu is not listed as a dishonest executor [4]. - The guarantee is deemed necessary and reasonable due to Laimei Longyu's stable operating conditions, aligning with the company's long-term business development needs [7]. Group 3: Board Approval and Current Guarantees - The board meeting on March 27, 2025, approved the guarantee with unanimous support [7]. - As of the announcement date, the total external guarantee balance is RMB 373.49 million, which is 6.20% of the company's audited net assets for 2024, with no overdue guarantees reported [7].

Summary of Key Points Core Viewpoint - The announcement details the provision of a guarantee by Guangxi Wuzhou Zhongheng Group Co., Ltd. for its wholly-owned subsidiary, Chongqing Laimeilongyu Pharmaceutical Co., Ltd., to secure a financing credit line of RMB 10 million from Hengfeng Bank, with a total guarantee amount of RMB 39.4 million [1][4]. Group 1: Guarantee Details - The guarantee amount for Chongqing Laimeilongyu is RMB 10 million, with an actual guarantee balance of RMB 39.4 million [1]. - The total external guarantee amount by the company and its subsidiaries is RMB 373.49 million, which represents 6.20% of the company's latest audited net assets [1][4]. - There are no overdue guarantees as of the date of the announcement [1][4]. Group 2: Internal Decision-Making Process - The company held board meetings on March 27, 2025, and April 28, 2025, to approve the guarantee proposal, which falls within the previously approved comprehensive credit limit of RMB 5 billion for 2025 [2]. - The total guarantee limit approved is up to RMB 2.5 billion, and this specific guarantee does not require further board or shareholder approval [2]. Group 3: Financial Overview of the Guaranteed Entity - Chongqing Laimeilongyu Pharmaceutical Co., Ltd. has total assets of RMB 535.71 million and total liabilities of RMB 304.30 million as of June 2025 [3]. - The company reported a net asset of RMB 231.41 million and an operating income of RMB 46.63 million for the first half of 2025 [3]. Group 4: Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary and reasonable as it aligns with the operational needs of Laimeilongyu and is within the legal and regulatory framework [3]. - The company’s board has confirmed that the risks associated with the guarantee are manageable and that it supports the long-term business development of the subsidiary [3].